Patient reperfusion preferences in acute myocardial infarction: Mortality versus stroke, benefits versus costs, high technology versus drugs

Canadian Journal of Cardiology

Volumn 21, Issue 5, 2005, Pages 423-431

  Tsui, W ^a   Pierre, K ^a   Massel, David ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Angioplasty; Decision making; Myocardial infarction; Patient preferences; Thrombolytic therapy

Indexed keywords

STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DRUG COST; DRUG USE; FEMALE; GOVERNMENT; HEALTH CARE COST; HEALTH SURVEY; HEART MUSCLE REPERFUSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MEDICAL TECHNOLOGY; MORTALITY; PATIENT ATTITUDE; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE PAYMENT; QUESTIONNAIRE; RISK ASSESSMENT; STROKE;

AGE FACTORS; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CEREBROVASCULAR ACCIDENT; COST-BENEFIT ANALYSIS; FEES, PHARMACEUTICAL; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; ONTARIO; PATIENT SATISFACTION; QUESTIONNAIRES; RISK FACTORS; STREPTOKINASE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 19644376595     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Ohman EM, Harrington RA, Cannon CP, Agnelli G, Cairns JA, Kennedy JW. Intravenous thrombolysis in acute myocardial infarction. Chest 2001;119(1 Suppl):253S-77S. (Erratum in 2002;121:310).
2. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994;343:311-22. (Erratum in 1994;19;343:742).
3. ISIS 3 (Third International Study of Infarct Survival) Collaborative Group. ISIS 3: A randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1992;339:753-70.
4. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI 2: A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet 1990;336:65-71.
5. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-82.
6. Califf RM, White HD, Van de Werf F, et al. One-year results from the Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries (GUSTO-I) trial. GUSTO-I Investigators. Circulation 1996;94:1233-8.
7. Tung CY, Granger CB, Sloan MA, et al. Effects of stroke on medical resource use and costs in acute myocardial infarction. GUSTO I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries Study. Circulation 1999;99:370-6.
8. Gore JM, Granger CB, Simoons ML, et al. Stroke after thrombolysis. Mortality and functional outcomes in the GUSTO-I trial. Global Use of Strategies to Open Occluded Coronary Arteries. Circulation 1995;92:2811-8.
9. Stanek EJ, Cheng JW, Peeples PJ, Simko RJ, Spinler SA. Patient preferences for thrombolytic therapy in acute myocardial infarction. Med Decis Making 1997;17:464-71.
10. Heyland DK, Gafni A, Levine MA. Do patients prefer tissue plasminogen activator (TPA) over streptokinase (SK)? An evaluation of the risks and benefits of TPA from the patient's perspective. J Clin Epidemiol 2000;53:888-94.
11. O'Meara JJ III, McNutt RA, Evans AT, Moore SW, Downs SM. A decision analysis of streptokinase plus heparin as compared with heparin alone for deep-vein thrombosis. N Engl J Med 1994;330:1864-9.
12. Cucherat M, Bonnefoy E, Tremeau G. Primary angioplasty versus intravenous thrombolysis for acute myocardial infarction. Cochrane Database Syst Rev 2003;3:CD001560.
13. Zahn R, Rustige J, Koch A, et al. Influence of the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (GUSTO-1) trial on the use of thrombolytics in Germany. ALKK Study Group. Arbeitsgemeinschaft der Leitenden Kardiologischen Krankenhausartze. Am J Cardiol 1997;80:1339-43.
14. Lorenzoni R, Pagano D, Mazzotta G, et al. Pitfalls in the economic evaluation of thrombolysis in myocardial infarction. The impact of national differences in the cost of thrombolytics and of differences in the efficacy across patient subgroups. Eur Heart J 1998;19:1518-24.
15. Lessler DS, Avins AL. Cost, uncertainty, and doctors' decisions. The case of thrombolytic therapy. Arch Intern Med 1992;152:1665-72.
16. Kent DM, Hayward RA, Griffith JL, et al. An independently derived and validated predictive model for selecting patients with myocardial infarction who are likely to benefit from tissue plasminogen activator compared with streptokinase. Am J Med 2002;113:104-11.
17. Weaver WD, Simes RJ, Betriu A, et al. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: A quantitative review. JAMA 1997;278:2093-8. (Erratum in 1998;279:1876).
18. Grines C, Patel A, Zijlstra F, Weaver WD, Granger C, Simes RJ, for the PCAT Collaborators. Percutaneous transluminal coronary angioplasty. Primary coronary angioplasty compared with intravenous thrombolytic therapy for acute myocardial infarction: Six-month follow up and analysis of individual patient data from randomized trials. Am Heart J 2003;145:47-57.
19. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: A quantitative review of the 23 randomised trials. Lancet 2003;361:13-20.
20. Magid DJ, Calonge BN, Rumsfeld JS, et al, for the National Registry of Myocardial Infarction 2 and 3 Investigators. Relation between hospital primary angioplasty volume and mortality for patients with acute MI treated with primary angioplasty vs thrombolytic therapy. JAMA 2000;284:3131-8.
21. Degeare VS, Dangas G, Stone GW, Grines CL. Interventional procedures in acute myocardial infarction. Am Heart J 2001;141:15-24.
22. Every NR, Parsons LS, Hlatky M, Martin JS, Weaver WD. A comparison of thrombolytic therapy with primary coronary angioplasty for acute myocardial infarction. Myocardial Infarction Triage and Intervention Investigators. N Engl J Med 1996;335:1253-60.
23. Tiefenbrunn AJ, Chandra NC, French WJ, Gore JM, Rogers WJ. Clinical experience with primary percutaneous transluminal coronary angioplasty compared with alteplase (recombinant tissue-type plasminogen activator) in patients with acute myocardial infarction: A report from the Second National Registry of Myocardial Infarction (NRMI-2). J Am Coll Cardiol 1998;31:1240-5.
24. Danchin N, Vaur L, Genes N, et al. Treatment of acute myocardial infarction by primary coronary angioplasty or intravenous thrombolysis in the "real world": One-year results from a nationwide French survey. Circulation 1999;99:2639-44.
25. Zahn R, Schiele R, Schneider S, et al. Decreasing hospital mortality between 1994 and 1998 in patients with acute myocardial infarction treated with primary angioplasty but not in patients treated with intravenous thrombolysis. Results from the pooled data of the Maximal Individual Therapy in Acute Myocardial Infarction (MITRA) Registry and the Myocardial Infarction Registry (MIR). J Am Coll Cardiol 2000;36:2064-71.
26. Kahneman D, Tversky A. Prospect theory: An analysis of decisions under risk. Econometrica 1979;47:262-91.
27. Grimes DA. Technology follies: The uncritical acceptance of medical innovation. JAMA 1993;269:3030-3.
28. Poses RM, Krueger JI, Sloman S, Elstein AS. Physicians' judgments of survival after medical management and mortality risk reduction due to revascularization procedures for patients with coronary artery disease. Chest 2002;122:122-33.
29. Kaptchuk TJ, Goldman P, Stone DA, Stason WB. Do medical devices have enhanced placebo effects? J Clin Epidemiol 2000;53:786-92.
30. Johnson AG. Surgery as a placebo. Lancet 1994;344:1140-2.
31. Ubel PA, DeKay ML, Baron J, Asch DA. Cost-effectiveness analysis in a setting of budget constraints - is it equitable? N Engl J Med 1996;334:1174-7.
32. Schwappach DL. Does it matter who you are or what you gain? An experimental study of preferences for resource allocation. Health Econ 2003;12:255-67.
33. Hallenbeck JL. What's the story - how patients make medical decisions. Am J Med 2002;113:73-4.
34. Montgomery AA, Fahey T. How do patients' treatment preferences compare with those of clinicians? Qual Health Care 2001;10(Suppl I):i39-i43.
35. Lopes LL. Between hope and fear: The psychology of risk. Adv Exp Soc Psychol 1987;20:255-95.
36. Reyna VF, Brainerd CJ. Fuzzy-trace theory and framing effects in choice: Gist extraction, truncation and conversion. J Behav Decis Making 1991;4:249-62.
37. Mellers BA, Schwartz A, Cooke AD. Judgement and decision making. Annu Rev Psychol 1998;49:447-77.
38. Dudley N. Importance of risk communication and decision making in cardiovascular conditions in older patients: A discussion paper. Qual Health Care 2001;10(Suppl I):i19-i22.